438 related articles for article (PubMed ID: 29338538)
1. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
Lyons T; Carhart-Harris RL
J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
[TBL] [Abstract][Full Text] [Related]
2. Effects of psilocybin therapy on personality structure.
Erritzoe D; Roseman L; Nour MM; MacLean K; Kaelen M; Nutt DJ; Carhart-Harris RL
Acta Psychiatr Scand; 2018 Nov; 138(5):368-378. PubMed ID: 29923178
[TBL] [Abstract][Full Text] [Related]
3. Psychedelics, Personality and Political Perspectives.
Nour MM; Evans L; Carhart-Harris RL
J Psychoactive Drugs; 2017; 49(3):182-191. PubMed ID: 28443703
[TBL] [Abstract][Full Text] [Related]
4. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
[TBL] [Abstract][Full Text] [Related]
5. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
6. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
[TBL] [Abstract][Full Text] [Related]
7. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
[TBL] [Abstract][Full Text] [Related]
8. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
[TBL] [Abstract][Full Text] [Related]
9. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
[TBL] [Abstract][Full Text] [Related]
10. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
11. Return of the psychedelics: Psilocybin for treatment resistant depression.
Patra S
Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
[TBL] [Abstract][Full Text] [Related]
12. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu A; Griffiths RR; Johnson MW
Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
15. Role of Psychedelics in Treatment-Resistant Depression.
Kamal S; Jha MK; Radhakrishnan R
Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
[TBL] [Abstract][Full Text] [Related]
16. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding.
Madsen MK; Fisher PM; Stenbæk DS; Kristiansen S; Burmester D; Lehel S; Páleníček T; Kuchař M; Svarer C; Ozenne B; Knudsen GM
Eur Neuropsychopharmacol; 2020 Apr; 33():71-80. PubMed ID: 32146028
[TBL] [Abstract][Full Text] [Related]
17. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW
J Psychopharmacol; 2018 Jul; 32(7):756-769. PubMed ID: 29938565
[TBL] [Abstract][Full Text] [Related]
18. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
[TBL] [Abstract][Full Text] [Related]
19. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ
J Psychiatr Res; 2023 May; 161():364-370. PubMed ID: 37004409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
